ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TRIM47 promotes cell viability, cell cycle progression, metabolic reprogramming, and inhibits apoptosis of glioma via the NF-κB signaling pathway.Translational cancer research · 2026Article
- TRIM47: molecular characteristics, disease-related mechanisms, and clinical translational value.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is an aggressive cancer with limited therapeutic targets and a poor prognosis. Aberrant energy metabolism plays a pivotal role in HCC progression by fulfilling the energy demands of rapidly proliferating tumor cells. In this study, tripartite motif-containing protein 47 (TRIM47) was found to be significantly upregulated in patient-derived HCC tissues, with clinical data revealing that higher TRIM47 expression correlates with poorer patient outcomes. Mechanistic investigations demonstrated that TRIM47 remodels energy metabolism by glycolytic reprogramming through its interaction with the K51 site of fructose-1,6-bisphosphatase (FBP1) through K48-linked ubiquitination, thereby promoting HCC proliferation and tumor metastasis. Rescue experiments and bortezomib intervention experiments further confirmed that FBP1 is essential for mediating the oncogenic effects of TRIM47 in HCC progression. To explore its therapeutic potential, TRIM47 siRNA was developed and loaded into poly (lactic acid)-DC-Chol nanoparticles (siTRIM47@PD NPs), which significantly reduced tumor growth and metastasis in an orthotopic HCC animal model, highlighting the potential of TRIM47 as a therapeutic target. Together, these findings underscore the pivotal role of TRIM47 in HCC progression through FBP1-mediated regulation of energy metabolism, and highlight siRNA-based TRIM47 targeting as a promising approach to improve HCC treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.